Clinical Trial

FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy

Name: FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy — clinical trial record (NCT06185569)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FREDO-ODX-23

Recruiting

View on ClinicalTrials.gov →

Summary

The aim of this study is to assess the clinical outcomes in real-life setting of early breast cancer RH+ HER2- patients with systemic therapy guided by Oncotype DX (ODX) Breast Recurrence Score®.

Trial Details

NCT Number	NCT06185569
Lead Sponsor	Centre Hospitalier Universitaire de Besancon
Conditions	Breast Cancer
Enrollment	4,500 participants
Start Date	2023-10-15
Primary Completion	2028-09 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2023-12-29